Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)
暂无分享,去创建一个
R. Coifman | B. Davis | H. Krumholz | Xiao Xu | Haiqun Lin | C. Furberg | Shu-Xia Li | E. Spatz | S. Pressel | A. Coppi | S. Dhruva | F. Warner | Chenxi Huang
[1] J. Spence,et al. Hypertension in blacks: insights from Africa. , 2017, Journal of hypertension.
[2] D. Sica,et al. Diuretics for Hypertension: A Review and Update. , 2016, American journal of hypertension.
[3] K. Bailey,et al. Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension. , 2016, American journal of hypertension.
[4] V. Fuster. No Such Thing as Ideal Blood Pressure: A Case for Personalized Medicine. , 2016, Journal of the American College of Cardiology.
[5] A. Hofman,et al. Mid- to Late-Life Trajectories of Blood Pressure and the Risk of Stroke: The Rotterdam Study , 2016, Hypertension.
[6] S. Anderson,et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.
[7] Jennifer S. Haas,et al. Trends in Prescription Drug Use Among Adults in the United States From 1999–2012 , 2016 .
[8] E. Boerwinkle,et al. The effects of genes implicated in cardiovascular disease on blood-pressure response to treatment among treatment-naïve hypertensive African Americans in the GenHAT study , 2015, Journal of Human Hypertension.
[9] Euan A Ashley,et al. The precision medicine initiative: a new national effort. , 2015, JAMA.
[10] S. Yusuf,et al. Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction and Stroke in Patients With Coronary Artery Disease , 2015, Hypertension.
[11] H. Krumholz. Big data and new knowledge in medicine: the thinking, training, and tools needed for a learning health system. , 2014, Health affairs.
[12] Jackson T. Wright,et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.
[13] Carmen Cadarso-Suárez,et al. smoothHR: An R Package for Pointwise Nonparametric Estimation of Hazard Ratio Curves of Continuous Predictors , 2013, Comput. Math. Methods Medicine.
[14] B. Davis,et al. Mortality and Morbidity During and After the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial , 2012, Journal of clinical hypertension.
[15] Stef van Buuren,et al. MICE: Multivariate Imputation by Chained Equations in R , 2011 .
[16] N. Kaplan. Chlorthalidone versus hydrochlorothiazide: a tale of tortoises and a hare. , 2011, Hypertension.
[17] J. Laragh,et al. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. , 2011, American journal of hypertension.
[18] C. Furberg. Renin test-guided drug treatment of hypertension: the need for clinical trials. , 2011, American Journal of Hypertension.
[19] S. Bangalore,et al. Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. , 2011, The American journal of medicine.
[20] John Fox,et al. OpenMx: An Open Source Extended Structural Equation Modeling Framework , 2011, Psychometrika.
[21] J. Laragh,et al. Pressor responses to antihypertensive drug types. , 2010, American journal of hypertension.
[22] Daniel J. Bauer,et al. Modeling Variability in Individual Development: Differences of degree or kind? , 2010, Child development perspectives.
[23] Heather M. Tavel,et al. Blood Pressure Trajectories and Associations With Treatment Intensification, Medication Adherence, and Outcomes Among Newly Diagnosed Coronary Artery Disease Patients , 2010, Circulation. Cardiovascular quality and outcomes.
[24] Nilam Ram,et al. Methods and Measures: Growth mixture modeling: A method for identifying differences in longitudinal change among unobserved groups , 2009, International journal of behavioral development.
[25] B. Davis,et al. Blood Pressure Control by Drug Group in the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2008, Journal of clinical hypertension.
[26] E. Boerwinkle,et al. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. , 2008, JAMA.
[27] A. Leuchter. General Approaches to Analysis of Course Applying Growth Mixture Modeling to Randomized Trials of Depression Medication , 2008 .
[28] H. Antonakoudis,et al. Blood pressure control and cardiovascular risk reduction. , 2007, Hippokratia.
[29] J. Laragh,et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial , 2004, The Lancet.
[30] Bengt Muthén,et al. Latent Variable Analysis: Growth Mixture Modeling and Related Techniques for Longitudinal Data , 2004 .
[31] B. Davis,et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.
[32] G. Mitchell,et al. Pulse pressure, arterial compliance and cardiovascular morbidity and mortality. , 1999, Current opinion in nephrology and hypertension.
[33] Michael A. Proschan,et al. Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 1996 .
[34] B R Davis,et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. , 1996, American journal of hypertension.
[35] D. Rubin. Multiple imputation for nonresponse in surveys , 1989 .